AR7 - Atypical retinoid 7
Axon 2679
CAS [80306-38-3]
MF C15H12ClNOMW 257.71
- Purity:99,7%
- Soluble in DMSO
Description
Atypical RARα receptor antagonist that stimulates CMA (chaperone-mediated autophagy) activity without detectable changes in other autophagic pathways, making cells more resistant to oxidative stress and proteotoxicity. AR7 is also known as a hypoxia targeted compound for cancer therapeutics (IC50 value 10 μM for inhibition of hypoxic cancer cell growth (MTT assay) in HepG2 cells while sparing ‘normoxic’ cells).
KEYWORDS:AR7 | supplier | RARα antagonist | Atypical retinoid 7 | AR-7 | AR 7 | CAS [80306-38-3] | Retinoic Acid | nuclear receptor | NR1B1 | chaperone-mediated | autophagy | CMA | hypoxia | cancer | neurodegenerative
| BC Das et al. Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4204-6. |
| J Anguiano et al. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. Nat Chem Biol. 2013 Jun;9(6):374-82. |
- Certificate of Analysis
- Material Safety Data Sheet
Chemical name
7-chloro-3-p-tolyl-2H-benzo[b][1,4]oxazine
Parent CAS No.
[80306-38-3]
Axon Medchem的业务之一，是独有的Axon Ligands配体库，在世界范围内，被认为是药物研发的标准。这其中，针对850余种生物靶标（包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等），Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库，Axon Medchem还是欧洲著名的CRO公司，主要针对生物活性分子和药物类似分子展开合成及协议开发工作，在过去的10年中，Axon Medchem已经发现了多种潜在药物分子，并在生物医药界享有一定的声誉。
暂无问答
本网站将在规定时间内给予删除等相关处理。
